Same sparkle, different story: how lab-grown diamonds are transforming the market 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
LINCOLN, Neb., April 17, 2018 -- National Research Corporation (NASDAQ:NRCIA) (NASDAQ:NRCIB) today announced that its shareholders approved the December 2017 announced recapitalization plan pursuant to which each share of class B common stock will be exchanged for one share of class A common stock plus $19.59 in cash, without interest. The recapitalization is effective as of 5:00 pm, CT, today and will result in the class B common stock ceasing to trade on the NASDAQ Global Market and being deregistered under the Securities Exchange Act of 1934. As of Wednesday, April 18, 2018, each share of the Company’s class A common stock will be reclassified as a share of common stock of the Company and the common stock continues to trade on the NASDAQ Global Market under the revised trading symbol “NRC.”
For more than 36 years, National Research Corporation has been a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers and other healthcare organizations in the United States and Canada. The Company’s solutions enable its clients to understand the voice of the customer with greater clarity, immediacy and depth.
Contact: Kevin R. Karas Chief Financial Officer 402-475-2525
